{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:02:50Z","timestamp":1792270970420,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032539","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.maturitas.2026.108914","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:49:28Z","timestamp":1773301768000},"page":"108914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes"],"prefix":"10.1016","volume":"208","author":[{"given":"Laura Baquedano","family":"Mainar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nieto-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Iglesias","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja Otero","family":"Garc\u00eda-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Porcel","family":"Llaneza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e8lia Torres","family":"Vilanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mu\u00f1oz","family":"Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim Calaf","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.maturitas.2026.108914_bb0005","first-page":"439","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.maturitas.2026.108914_bb0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clbc.2023.08.003","article-title":"Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis","volume":"23","author":"Comini","year":"2023","journal-title":"Clin. Breast Cancer"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108914_bb0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO\u2013ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108914_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068053","article-title":"GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy - study protocol","volume":"13","author":"Vergauwen","year":"2023","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.maturitas.2026.108914_bb0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jogc.2021.09.001","article-title":"Guideline no. 422b: menopause and genitourinary health","volume":"43","author":"Johnston","year":"2021","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.maturitas.2026.108914_bb0030","first-page":"183","article-title":"Vulvovaginal atrophy in women with and without a history of breast cancer: Baseline data from the PatiEnt satisfactiON studY (PEONY) in Italy","volume":"1","author":"Meriggiola","year":"2024","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.108914_bb0035","doi-asserted-by":"crossref","DOI":"10.61622\/rbgo\/2025rbgo46","article-title":"Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis","volume":"47","author":"Santos","year":"2025","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"10.1016\/j.maturitas.2026.108914_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2026.108858","article-title":"The window of opportunity for treating vulvovaginal atrophy in menopause: insights from oestrogen receptor distribution and age-related changes","author":"Gonz\u00e1lez","year":"2026","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108914_bb0045","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer","volume":"138","year":"2021","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108914_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GME.0000000000001260","article-title":"The burden of vulvovaginal atrophy on women\u2019s daily living: Implications on quality of life from a face-to-face real-life survey","volume":"26","author":"Nappi","year":"2019","journal-title":"Menopause"},{"issue":"9407","key":"10.1016\/j.maturitas.2026.108914_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2014is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108914_bb0060","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/GME.0000000000001131","article-title":"Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial","volume":"25","author":"Diem","year":"2018","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108914_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/GME.0000000000001194","article-title":"WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history","volume":"26","author":"Kingsberg","year":"2019","journal-title":"Menopause"},{"issue":"10204","key":"10.1016\/j.maturitas.2026.108914_bb0070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2026.108914_bb0075","first-page":"371","article-title":"Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases","volume":"28","author":"Vinogradova","year":"2020","journal-title":"The BMJ."},{"key":"10.1016\/j.maturitas.2026.108914_bb0080","series-title":"Breast Cancer Research and Treatment","article-title":"Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials","volume":"152","author":"Mazzarello","year":"2015"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108914_bb0085","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or Vaginal Hormone Therapy after Early Breast Cancer: A Danish Observational Cohort Study","volume":"114","author":"Cold","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108914_bb0090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108914_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.maturitas.2026.108914_bb0100","series-title":"American Journal of Obstetrics and Gynecology","first-page":"262","article-title":"Vaginal estrogen use in breast cancer survivors: A systematic review and meta-analysis of recurrence and mortality risks","volume":"232","author":"Beste","year":"2025"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108914_bb0105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10549-023-06871-w","article-title":"Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk","volume":"198","author":"Sund","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.108914_bb0110","first-page":"164","article-title":"Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients","volume":"1","author":"Li","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.maturitas.2026.108914_bb0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jogc.2021.09.005","article-title":"Guideline no. 422d: menopause and sexuality","volume":"43","author":"Wolfman","year":"2021","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.maturitas.2026.108914_bb0120","author":"Women'\u2019s Health Initiative"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108914_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.108914_bb0130","series-title":"A systematic review of randomised clinical trials \u2013 The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors","first-page":"222","volume":"vol. 29","author":"Hussain","year":"2023"},{"key":"10.1016\/j.maturitas.2026.108914_bb0135","article-title":"Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion","volume":"102880","author":"Kastora","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.maturitas.2026.108914_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103327","article-title":"268MO Safety of vaginal estrogen therapy after early-stage breast cancer: a nationwide population-based target trial emulation","volume":"9","author":"Dumas","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.maturitas.2026.108914_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2022.08.008","article-title":"Eligibility criteria for menopausal hormone therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT eligibility criteria group","volume":"166","author":"Mendoza","year":"2022","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108914_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: Effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.108914_bb0155","series-title":"Systemic estradiol levels with low-dose vaginal estrogens","first-page":"361","volume":"vol. 27","author":"Santen","year":"2020"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108914_bb0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido inwomen receiving aromatase inhibitors for early-stage breast cancer a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108914_bb0165","first-page":"187","article-title":"Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"29","author":"Streff","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.maturitas.2026.108914_bb0170","series-title":"The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis","first-page":"e731","volume":"vol. 19","author":"Pavlovi\u0107","year":"2019"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108914_bb0175","doi-asserted-by":"crossref","first-page":"e1846","DOI":"10.1634\/theoncologist.2020-0417","volume":"25","author":"S\u00e1nchez-Rovira","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.maturitas.2026.108914_bb0180","article-title":"Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis","volume":"13","author":"L\u0151czi","year":"2024","journal-title":"Journal of Clinical Medicine. Multidisciplinary Digital Publishing Institute (MDPI)"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108914_bb0185","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.maturitas.2026.108914_bb0190","first-page":"10","article-title":"Executive summary: the AUA\/SUFU\/AUGS guideline on genitourinary syndrome of menopause","author":"Kaufman","year":"2024","journal-title":"Urogynecology"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108914_bb0195","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.108914_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.maturitas.2021.04.005","article-title":"Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide","volume":"148","author":"Hirschberg","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.108914_bb0205","article-title":"Updated Labeling for Menopausal Hormone Therapy","author":"Makary","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2026.108914_bb0210","series-title":"Cochrane Database of Systematic Reviews","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"2016","author":"Lethaby","year":"2016"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108914_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.maturitas.2012.12.004","article-title":"Women\u2019s preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy","volume":"74","author":"Mattsson","year":"2013","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:26:13Z","timestamp":1779485173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S0378512226000915"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108914","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108914"}}